AIDS Virus Co-Discoverer, Jean-Claude Chermann, Joins Aethlon Medical Science Advisory Board.

Business Editors/Health/Medical Writers

LA JOLLA, Calif.--(BUSINESS WIRE)--Oct. 22, 2003

Aethlon Medical, Inc. (OTCBB:AEMD) announced today that Jean-Claude Chermann, Ph.D., has joined its Science Advisory Board. Dr. Chermann is a pioneer in the study of retroviruses, and was the principal investigator of the research team that collaborated in the first isolation and characterization of HIV (The AIDS Virus) at the Pasteur Institute in 1983.

Dr. Chermann was also the Director of Research of INSERM (French National Institute of Health and Medical Research) and held the additional position of Director of Research of Unit INSERM U322 on "Retrovirus and Associated Diseases" from 1989 until June 2001 when he accepted his current role as Chief Scientific Director of Urrma Biopharma based in Montreal, Canada, and Research & Development Director of URRMA R&D, based in Aubagne, France.

Included among Dr. Chermann's research publications on HIV/AIDS are:

-- First isolation of HIV, description of the cytopathic effect

for CD4 +cells, the CD4 +cells as target and the isolation of

the virus in haemophiliacs and in the African people.

-- The confirmation that HIV is a retrovirus by the description

of the reverse transcriptase. The demonstration that the HIV

retrovirus is a lentivirus.

-- The demonstration of the transmission by blood by isolating

the virus in the donor and in the recipient. The description

of the methods of inactivation of HIV.

-- The first inoculation of chimpanzees and the demonstration of

this infection.

-- The association of persistent general lymphadenopathy and the

infection with HIV.

-- The first use of an anti-retroviral agent in humans for the

treatment of AIDS patients.

-- The first demonstration of the infection by the detection of

antibodies in US patients.

-- The demonstration of the transmission by needle sharing and

heterosexual transmission.

-- The first description of the genomic variability of HIV.

About Aethlon Medical

Aethlon Medical is developing therapeutic devices that treat HIV/AIDS, Hepatitis-C, and other infectious diseases. In pre-clinical testing, Aethlon's lead product, AEMD-45 removed 55% of HIV from human blood in three hours and in excess of 85% in twelve hours. AEMD-45 is also able to clear 90% of toxic proteins (gp-120) that deplete immune cells in one hour.

AEMD-45, like all product offerings from Aethlon Medical, is developed from an expansive platform technology known as the Hemopurifier(TM), which employs a proprietary method to increase the capability of FDA cleared artificial kidneys (hemodialysis cartridges) to bind infectious viruses and toxic proteins from human blood before cells are infected. In January of 2003, the Company completed early stage blood studies of its HCV-Hemopurifier, which documented the ability to remove 58 percent of the Hepatitis-C virus from infected blood in two hours. For more information, visit the company's Web site at www.AethlonMedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.